

For Immediate Release
Alembic Pharmaceuticals Limited
Consolidated Results for quarter ended 31.12.2013

Revenues up 31% at Rs 487 crores against Rs. 372 crores in PY
PBT up 48% at Rs 88.83 crores against Rs. 60.09 crores in PY

Editors Synopsis

- Net sales up 31% at Rs 487 crores for the quarter against Rs 372 crores in corresponding quarter last year
- Profit before tax up 48% at Rs 88.83 crores against Rs 60.09 crores in corresponding quarter last year
- Net profit after tax up 37% for the quarter at Rs 65.93 crores vis-à-vis Rs 48.27 crores in corresponding quarter last year
- EBITDA at 21% at Rs 102.23 crores vs 18.64% at Rs 69.36 crores in corresponding quarter last year
- International Generic Formulations sales up 112% for the quarter at Rs 130 crores against Rs 61 crores in corresponding quarter last year
- India Branded formulations sales up 15% for the quarter at Rs 230 crores against Rs 200 crores in corresponding quarter last year.
- Net sales up 22% for YTD DEC 13 at Rs 1403 crores against Rs 1148 crores for corresponding period last year
- PBT up 52% for YTD Dec 13 at Rs 229.8 crores against Rs 151.2 crores for corresponding period last year

Vadodara, 22nd January, 2014

Alembic Pharmaceuticals Limited reported a 31% increase in revenues to Rs 486.74 crores for the quarter ended 31st December 2013, compared to Rs 372.05 crores in the corresponding quarter last year.

The Company posted 48% growth in profit before tax at Rs. 88.83 crores for the quarter ended 31st December 2013 against Rs 60.09 crores posted in corresponding quarter last fiscal.

The net profit grew by 37% at Rs 65.93 crores for the quarter ended 31st December 2013 against Rs 48.27 crores in corresponding quarter last fiscal.

EBIDTA margins for quarter ended 31st December 13 up at 21% to Rs 102.23 crores from 18.64% at Rs 69.36 crores for corresponding quarter last year.

The company also reported 22% increase in revenue for YTD Dec 13 to Rs 1403.19 crores against Rs 1147.64 crores for corresponding period last year.

The company also posted 52% growth in profit before tax at Rs. 229.82 crores for YTD Dec 13 against Rs. 151.17 crores for corresponding period last year. The Company also reported 43% growth in net profit for YTD Dec 13 at Rs. 174.21 crores against Rs. 121.60 crores in corresponding period last year.

India Branded Formulations Business

The India Branded formulations business posted sales of Rs. 229.57 crores against Rs. 199.85 crores with a 15% growth over the corresponding quarter of the previous year.

As per ORG IMS, Alembic has market share of 1.76% (MAT-Nov 13). Gestofit has featured as Company's 5th brand in top 300 brands list of IMS-ORG.

Specialty and Acute segments grew by 22% and -2% respectively in current years (MAT-Nov 13) versus Industry growth rate of 11% and 2% respectively.

International Generics

International Generic Formulation posted growth of 112% and posted sales of Rs. 129.62 crores against Rs. 61.05 crores over the corresponding quarter last year.

During the quarter 1 ANDA application were filed taking cumulative ANDA filings of the Company to 60. 1 ANDA approval was received during the quarter. Cumulative ANDA approvals now stand at 31 (including 4 tentative approvals). During the quarter 2 DMF applications were filed taking cumulative DMF filings of the Company to 64.

Summary of Total Revenue is as under:

(Rs. in Lacs)

Particulars	Q3 FY14	Q3 FY13	% Change	YTD Dec FY14	YTD Dec FY13	% Change
Formulation						
India Branded	22957	19985	15%	66637	58997	13%
India Generics	2736	2779	(-) 2%	8663	8878	(-) 2%
International Branded	1967	1503	31%	4624	3126	48%
International Generics	12962	6105	112%	32876	15811	108%
API	7564	6699	13%	26081	27189	(-) 4%
Export Incentives	488	134	-	1438	763	-
Total	48674	37205	31%	140319	114764	22%

The Profit break-up is as under:

(Rs. in Lacs)

Particulars	Q3 FY14	Q3 FY13	% Change	YTD Dec FY14	YTD Dec FY13	% Change
Operating Income	10223	6936	47%	26642	18637	43%
Profit Before Tax	8883	6009	48%	22982	15117	52%
Net Profit after Tax	6593	4827	37%	17421	12160	43%

About Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities all over the world including the US FDA. Alembic is one of the leaders in branded generics in India. Alembic's brands, marketed through a marketing team of over 3900 are well recognized by doctors and patients.

Information about the company can be found at www.alembic-india.com; (reuters:ALEM.NS) (bloomberg:ALPM) (nse:APLLTD) (bse:533573)

For more information contact:

Alembic Pharmaceuticals Limited

Ajay Kumar Desai

Phone: +91 22 – 306 11681

Email: ajay.desai@alembic.co.in

Mitanshu Shah

Phone: +91 265 – 3007630

Email: mitanshu.shah@alembic.co.in